CN102811721A - 治疗与5-fu或5-fu前药联合的dpd抑制剂给药相关的神经毒性的方法 - Google Patents

治疗与5-fu或5-fu前药联合的dpd抑制剂给药相关的神经毒性的方法 Download PDF

Info

Publication number
CN102811721A
CN102811721A CN2010800562916A CN201080056291A CN102811721A CN 102811721 A CN102811721 A CN 102811721A CN 2010800562916 A CN2010800562916 A CN 2010800562916A CN 201080056291 A CN201080056291 A CN 201080056291A CN 102811721 A CN102811721 A CN 102811721A
Authority
CN
China
Prior art keywords
eniluracil
dpd
prodrug
dpd inhibitor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800562916A
Other languages
English (en)
Chinese (zh)
Inventor
T·斯佩克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fennec Pharmaceuticals Inc
Original Assignee
Adherex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adherex Technologies Inc filed Critical Adherex Technologies Inc
Publication of CN102811721A publication Critical patent/CN102811721A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2010800562916A 2009-10-14 2010-10-14 治疗与5-fu或5-fu前药联合的dpd抑制剂给药相关的神经毒性的方法 Pending CN102811721A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25144909P 2009-10-14 2009-10-14
US61/251,449 2009-10-14
PCT/US2010/052734 WO2011047195A1 (en) 2009-10-14 2010-10-14 Treating neurotoxicity associated with combinations of 5 - fu or its prodrugs and dpd inhibitors

Publications (1)

Publication Number Publication Date
CN102811721A true CN102811721A (zh) 2012-12-05

Family

ID=43466528

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800562916A Pending CN102811721A (zh) 2009-10-14 2010-10-14 治疗与5-fu或5-fu前药联合的dpd抑制剂给药相关的神经毒性的方法

Country Status (14)

Country Link
US (1) US8658618B2 (https=)
EP (1) EP2488182B1 (https=)
JP (2) JP2013508293A (https=)
KR (1) KR20120127709A (https=)
CN (1) CN102811721A (https=)
AU (1) AU2010306698B2 (https=)
BR (1) BR112012008951A2 (https=)
CA (1) CA2777546C (https=)
CO (1) CO6541596A2 (https=)
EA (1) EA201270551A1 (https=)
ES (1) ES2644237T3 (https=)
IL (1) IL219179A0 (https=)
MX (1) MX2012004383A (https=)
WO (1) WO2011047195A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089004A1 (en) * 2012-12-04 2014-06-12 Adherex Technologies, Inc. Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
IL321302A (en) * 2022-12-06 2025-08-01 Elion Oncology Inc Combined use of anilouracil and capecitabine for cancer treatment
WO2025015267A1 (en) * 2023-07-13 2025-01-16 Processa Pharmaceuticals, Inc. Methods of personalizing cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817664A (en) * 1990-09-26 1998-10-06 Glaxo Wellcome Inc. Uracil reductase inactivators
CN101068549A (zh) * 2004-12-03 2007-11-07 阿迪赫里克斯技术公司 与5－fu和5－fu前药组合施用dpd抑制剂的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5687599A (en) 1979-12-19 1981-07-16 Yamasa Shoyu Co Ltd E 55 22halogenovinyl arabinofuranosyluracil and its preparation
GB8629892D0 (en) 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US5157114A (en) 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
JP3094036B2 (ja) 1990-07-19 2000-10-03 ザ ウエルカム ファウンデーション リミテッド 酵素不活性化剤
US5476855A (en) 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
NZ330360A (en) 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040028687A1 (en) 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817664A (en) * 1990-09-26 1998-10-06 Glaxo Wellcome Inc. Uracil reductase inactivators
CN101068549A (zh) * 2004-12-03 2007-11-07 阿迪赫里克斯技术公司 与5－fu和5－fu前药组合施用dpd抑制剂的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用

Also Published As

Publication number Publication date
ES2644237T3 (es) 2017-11-28
US20110130359A1 (en) 2011-06-02
WO2011047195A1 (en) 2011-04-21
EP2488182B1 (en) 2017-07-19
AU2010306698B2 (en) 2016-05-26
US8658618B2 (en) 2014-02-25
AU2010306698A1 (en) 2012-05-17
MX2012004383A (es) 2012-08-23
JP2013508293A (ja) 2013-03-07
EA201270551A1 (ru) 2012-12-28
JP2016014051A (ja) 2016-01-28
BR112012008951A2 (pt) 2019-09-24
CO6541596A2 (es) 2012-10-16
KR20120127709A (ko) 2012-11-23
EP2488182A1 (en) 2012-08-22
CA2777546A1 (en) 2011-04-21
IL219179A0 (en) 2012-06-28
CA2777546C (en) 2019-11-05

Similar Documents

Publication Publication Date Title
US20130184232A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
Hong et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS‐102 in patients with solid tumors
CN114727996A (zh) 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
KR20070104559A (ko) α,α,α-트리플루오로티미딘과 티미딘포스포릴라아제저해제를 배합한 항암제
Laille et al. Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies
US7799783B2 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
Asselah et al. Interferon therapy for chronic hepatitis B
AU2010306698B2 (en) Treating neurotoxicity associated with combinations of 5 - FU or its prodrugs and DPD inhibitors
Keam et al. Brivudin (bromovinyl deoxyuridine)
JP2007508299A (ja) 全身性抗癌治療の間の器官保護のための方法、組成物、およびキット
JP6845332B2 (ja) がん治療用医薬組成物及びその使用
AU2012200856B2 (en) Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
US20080255168A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
HK1110531A (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
WO2014089004A1 (en) Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
Yano et al. 67 in vitro characterization of a novel dUTPase inhibitor, TAS-114, as a fluoropyrimidine enhancer
WO2022014025A1 (ja) 血液がんの新規治療法及び新規治療剤
Cats Maarten J. Deenen, Luc Dewit, Henk Boot, Ria Dubbelman, Jos H. Beijnen, Jan HM Schellens
Tanaka et al. 66 Trifluorothymidine Incorporation into DNA is the Primary Mechanism of Action of TAS-102, and Leads to Markedly Prolonged Survival in a Mouse Model

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121205